O n 24 April 2009, the World Health Organization (WHO) reported that seven patients in the USA (five in California and two in Texas) and three patients in Mexico had become infected with a new strain of influenza, subsequently designated the new influenza A virus (H1N1/09) (1) .
Molecular biological testing revealed that the new influenza A virus (H1N1/09) possesses the following genes: two genes derived from the strain of avian influenza that infected the Eurasian swine population in 1979; three corresponding to classical influenza A (H1N1) from the North American swine population; two representing a triple reassortment (recombination of various gene segments present in the gene pool) from the North American swine population; and one gene homologous to the strain of human influenza A that reached the human population in 1968 with avian influenza (2) .
Thus, the new influenza A virus (H1N1/09) contains only a single gene segment (PB1) corresponding to the two seasonal influenza strains (H1N1 and H3N2), namely, a gene segment that entered the H3N2 virus in 1968 from an avian source and has been circulating since then. Its remaining gene segments come from swine influenza viruses of Eurasian and North American origin and from avian influenza viruses of recent decades.
On 5 May 2009, 1124 cases had already been reported worldwide. In view of ongoing human-tohuman transmission in multiple regions of the world, the WHO declared a phase 6 pandemic on 11 June 2009. This was the start of the new influenza A virus (H1N1/09) pandemic (3) . By this time, nearly 30 000 persons had become ill with the new virus worldwide, and 144 had died in 74 countries. In Germany, the virus was found in more than 160 persons up to 13 June 2009. About half of all cases were in the state of North Rhine-Westphalia.
Physicians in the Department of Gastroenterology, Hepatology, and Infectious Disease and the Department of General Pediatrics at the Düsseldorf University Hospital tested persons with suspected H1N1/09 infection for the presence of the virus. In this article, we report our experience with the new influenza virus during the first wave of the pandemic in the summer of 2009.
Methods
Testing for the new influenza A virus (H1N1/09) began in late April 2009 (calendar week 18). The persons tested included patients with flu-like symptoms and contacts of persons who had become ill because of the new influenza A virus (H1N1/09) and who had been referred to us for testing by the Düsseldorf Health Department after screening at the Düsseldorf Airport and the bus terminal, by medical colleagues in private practice, and by other hospitals. Some of the patients came on their own initiative.
All patients were clinically examined in a treatment area that was separate from the hospital's Emergency Department, and in which anti-infectious precautions for the medical staff were observed in accordance with Directive 609 of the Committee for Biological Agents of the German Federal Institute for Occupational Safety and Health. These precautions included disposable gowns, protective gloves, a tightly fitting surgical mask (FFP-2), and, if needed, an eye shield.
Initially, various types of biological sample, including nasal swabs, throat-rinsing fluid, and pharyngeal swabs, were tested with the polymerase chain reaction (PCR) in parallel with a rapid influenza test. The rapid test used is said to be 94% sensitive and 90% specific for influenza A (4). The PCR tests were performed with the technique recommended by the Robert Koch Institute (5), which can reportedly detect concentrations as low as 384 RNA copies per mL (95% confidence interval, 273 to 876 RNA copies per mL) with 100% specific ity (6) . The first positive test was on 20 May 2009: a family of three returning from a trip to the USA tested positive for the new influenza A virus (H1N1/09) with the PCR test, but the rapid influenza test was negative. Thereafter, false negative results were repeatedly obtained with rapid influenza tests despite the presence of a verified H1N1 test, and the rapid test was dropped from further testing. The authors found that, among all sample types, the virus was most reliably demonstrated with deep nasal swabs.
At the start of the wave of infection, all patients that tested positive (n = 60) were kept in the hospital under quarantine, in view of the lack of clinical experience at that time and in accordance with the instructions of the health authorities. This is a reasonable strategy to slow the spread of disease at the beginning of a first wave of infection (7) . All these patients were treated with oseltamivir until their first nasal swab tested negative, as recommended by the guidelines. Oseltamivir has not been approved for children under one year old; nevertheless, because infants are particularly at risk, the WHO has now published a recommendation that oseltamivir should be used (8) . Thus, after meticulous consideration of the benefits and risks, infants that have tested positive for H1N1 infection during a pandemic can be treated with oseltamivir, as long as their parents have given informed consent. Later on in the period of time covered by this article, the number of cases rose markedly, and hospitalization was reserved for severely ill patients Overall depiction of the number of tests performed for the new influenza A virus (H1N1/09) by calendar week
FIGURE 2
Age distribution of persons testing positive for the new influenza A virus (H1N1/09) who had probably contracted the infection abroad (n=379) or in Germany (n=63)
for whom quarantine at home would have been inadequate medical treatment.
The criteria for suspected infection with the new influenza A virus (H1N1/09) were changed as of 24 August 2009 (calendar week 35): since that date, the suspicion of infection requires that the patient suffer from otherwise unexplained fever (>38.0°C) and cough (9) . Because of this change in criteria, the clinical manifestations were evaluated only up to 24 August 2009 (n = 411). Fewer patients were tested for the new influenza A virus (H1N1/09) afterward.
Results
The number of samples that tested positive and negative for the new influenza A virus (H1N1/09) in each calendar week is shown in Figure 1 . There is a clearly recognizable, sharp increase in positive samples that began in week 29 and reached a peak in week 31. 3372 tests were performed up to and including week 38; 450 persons had a positive test for the new influenza A virus (H1N1/09) during this time. Aside from the detection of the new influenza A virus (H1N1/09), testing also revealed an influenza A (H3N2) infection in four patients and a seasonal influenza A (H1N1) infection in two patients. Three of the tested patients were also tested for HIV, with their informed consent, on the basis of their history. This testing led to the initial diagnosis of HIV infection in all three cases. eFigure 1 shows the age of persons testing positive for the new influenza A virus (H1N1/09) and the countries in which they contracted the infection, as a function of time. The graph clearly reflects the fact that nearly all cases in the first few weeks were among business travelers and tourists returning from North America (n = 25). In calendar week 24, there was an outbreak of infection among members of the Japanese community in Düsseldorf. The disease had been transmitted to pupils of the Düsseldorf International School during a class trip; the Düsseldorf Health Department reports that, in all, about 80 members of the Düsseldorf Japanese community were infected. The outbreak was rapidly and successfully controlled within that community. As a result of the quarantine measures that were put into effect, no further cases with a proven connection to this outbreak were diagnosed from calendar week 26 onward.
Later, there were sporadic cases among persons returning from travel to England (n = 18) and a small number of imported infections (n = 26) from other countries (Bulgaria: n = 9, Greece: n = 3, Italy: n = 3, Malta: n = 2, Egypt: n = 1, Brazil: n = 1, Denmark: n = 1, Corsica: n = 1, Mexico: n = 1, the Netherlands: n = 3; Singapore: n = 1), as well as 63 infections contracted in Germany, most of which could be traced to contact with persons who had already tested positive for the new influenza A virus (H1N1/09).
The largest group of infected persons consisted of returning travelers from Spain (n = 310), most of them adolescents. Most cases were diagnosed during the first half (calendar weeks 28 through 30) of the official summer vacation from school in the State of North Rhine-Westphalia (2 July to 14 August 2009) (see eFigure 2). This explains the age distribution of infected persons, as shown in Figure 2 and eFigure 3: there is a peak in the number of cases among 15-to 25-year-olds. The style of travel and other behavioral patterns specific to this age group are likely to have promoted the rapid dissemination of the new influenza A virus (H1N1/09) within it. Among the cases acquired in Germany, the age distribution was broader. Only two infants (8 and 12 months old) tested positive for the new influenza A virus (H1N1/09); treatment with oseltamivir was discussed with their parents, but we do not know whether such treatment was actually provided. The Table shows the age distribution of patients that tested positive as well as the place (Germany or another country) in which the infection was contracted. Figure 3 provides an overview of the clinical manifestations of persons testing positive for the new influenza A virus (H1N1/09) at the time of their presentation to the authors' hospital. Patient data were evaluated up to and including calendar week 34 (n = 411), because the criteria for suspected infection with the new influenza A virus (H1N1/09) were changed on 24 August 2009: after this date, only patients with otherwise unexplained fever (>38.0°C) and cough were considered potentially infected with the new virus (9) . While some patients manifested nearly the entire clinical spectrum of all of the listed manifestations, there were others who were only mildly affected and then rapidly recovered. Only about one-third of all patients had a temperature above 38.0°C on presentation, but about two-thirds had at least a history of fever. Most patients, including pediatric patients, presented to the hospital within the first three days of illness (Figure 4) .
At the start of the wave of infection, all persons testing positive for the new influenza A virus (H1N1/09) were admitted to the hospital and kept under quarantine. This was done in accordance with a directive of the health authorities as a strict containment measure to minimize the spread of the disease, whose severity could not yet be judged in this early period (7) .
Later on, as the number of cases rapidly increased, hospital admission was reserved for severely ill persons who could not be cared for adequately under quarantine at home. Two of these persons additionally suffered from mycoplasma pneumonia. Detailed clinical data are only available for the hospitalized patients, and an analysis of all the available data would have created a statistical bias toward more severe illness. To circumvent this problem, we restricted the analysis of laboratory parameters to the first 60 patients who tested positive for the new influenza A virus (H1N1/09), because all of these patients were hospitalized regardless of the severity of their illness.
The clinical manifestations in most patients included fever, myalgia, arthralgia, headache, and respiratory symptoms such as cough, runny nose, and sore throat. The median core temperature on admission to the hospital was 37.8°C (range, 36.4 to 39.4°C). The C-reactive protein (CRP) concentration was generally only mildly elevated (median, 1.0 mg/dL; range, <0.3 to 23.9 mg/ dL). The normal CRP value is under 0.5 mg/dL.
The measured leukocyte counts were in the low normal range (median, 5.8 × 1000/µL; range, 2.7 to 19.6 × 1000/µL). Patients with markedly elevated CRP Information given by patients on presentation about the duration of symptoms to date (e.g., fever, headache, sore throat, and pain in the limbs) concentrations and leukocytosis generally had an additional bacterial focus of infection, e.g., a urinary tract infection or purulent tonsillitis ( Figures 5, 6 , and 7). All patients were treated with oseltamivir. Most of the initially symptomatic patients were free of symptoms within 3 days. The median duration of treatment with oseltamivir was 5 days. Most patients had mild side effects, such as headache and gastrointestinal complaints (nausea, vomiting), which were easily controlled with symptomatic treatment. No serious side effects were observed. The median interval to the first PCR-negative deep nasal swab was 4 days (range, 1 to 10 days). There has not yet been any evidence of oseltamivir resistance.
Discussion
The clinical data reported here indicate that infection with the new influenza A virus (H1N1/09) during the period of investigation (up to mid-September 2009) was a rather mild disease that was usually acquired outside the country. This observation holds for children with the disease as well. The authors' experience with the new influenza A virus (H1N1/09) is comparable to the data published to date from other countries (10-17, e1-e3). More and more patients, however, are contracting the disease within Germany, and the average age of these patients is higher. If the number of cases continues to rise, it is highly likely that severe disease courses and fatal cases will be seen in Germany as well as in other European countries (18) . As of 1 November 2009, 6 deaths in Germany had been causally connected to the new influenza A virus (H1N1/09) (19) (20) (21) (22) (23) (24) ; as of 10 November 2009, this number had risen to 9. Treatment of the new influenza A virus (H1N1/09) with oseltamivir is relatively well tolerated, but it causes side effects including headache, gastrointestinal complaints (nausea, vomiting), and disturbed concentration, as was recently found in a study of schoolchildren in England (25) . In the present study, we found that the median duration of treatment until the first negative nasal swab was four days. According to data In summary, the new influenza A virus (H1N1/09) characteristically caused mild illness up to mid-September 2009. This article describes the beginning of the pandemic. The number of infections acquired within Germany, and the number of resulting deaths, can be expected to rise markedly over its further course. The infection-control measures undertaken to date have enabled us to withstand the first wave of the pandemic with good success. There is no evidence yet of any development of oseltamivir resistance in Germany.
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